Rigel awards new hires 13,375 RSUs under its inducement plan
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the grant of 13,375 restricted stock units (RSUs) to six new non-executive employees under its Inducement Plan. These awards, made in accordance with NASDAQ Listing Rule 5635(c)(4), will vest over four years, with 25% vesting annually. This move is aimed at attracting and retaining talent, and it resulted in a positive market reaction, with RIGL stock gaining 5.50%.
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced inducement grants to six non-executive employees under NASDAQ Listing Rule 5635(c)(4). These grants consist of 13,375 restricted stock units, vesting over four years at 25% annually. The awards are part of Rigel's Inducement Plan, approved by its Compensation Committee, to attract new talent.
RI2 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rigel Pharmaceuticals, Inc. (RI2) stock for 2027, including analyst price targets and ratings. It also offers key financial metrics such as EPS, revenue, net income, and EBITDA, along with historical stock performance and upcoming earnings dates. The content addresses frequently asked questions about the company's stock, trading information, and employee count.
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals, Inc. announced the appointment of Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer. Dr. Hannah, who previously served on Rigel's Board of Directors, brings extensive experience in oncology drug development. She will lead the advancement of Rigel's pipeline, including R289 for lower-risk MDS and vepdegestrant for metastatic breast cancer.
Press Release: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
This press release announces that Rigel Pharmaceuticals has appointed Dr. Alison L. Hannah as its new Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who has been a member of Rigel's Board of Directors since 2019, brings extensive experience in drug development and medical affairs from her previous roles at Genentech/Roche. Rigel's CEO, Raul Rodriguez, expressed enthusiasm for her appointment, highlighting her strategic insights and commercial acumen as valuable assets for the company's future growth.
Alison Hannah joins Rigel (NASDAQ: RIGL) as new EVP and Chief Medical Officer
Rigel Pharmaceuticals (NASDAQ: RIGL) has appointed Alison L. Hannah, M.D. as its new Executive Vice President and Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who previously served on Rigel's Board of Directors, resigned from the board upon her appointment to this executive role. Her appointment follows the departure of Lisa Rojkjaer, M.D., who ceased serving as EVP and CMO on June 25, 2026.
Rigel Pharmaceuticals Appoints Alison L. Hannah as Chief Medical Officer
Rigel Pharmaceuticals Inc. has appointed Alison L. Hannah, M.D., as its new executive vice president and chief medical officer, effective July 1. Hannah, who previously served on Rigel’s Board of Directors, brings extensive experience in oncology drug development and will lead the company's clinical programs. This appointment strengthens Rigel’s leadership as it advances its oncology and hematology pipeline, including the lead investigational candidate R289 and the recently added vepdegestrant program.
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals, Inc. has appointed Alison L. Hannah, M.D. as its new Executive Vice President and Chief Medical Officer. Dr. Hannah, who previously served on Rigel's Board of Directors, brings extensive experience in oncology drug development. She will lead the company's clinical development pipeline, including R289 for lower-risk MDS and vepdegestrant for metastatic breast cancer, succeeding Lisa Rojkjaer, M.D.
(RIGL) Movement as an Input in Quant Signal Sets
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI-generated signals, highlighting strong near and mid-term sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward short setup. It details three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points, along with a multi-timeframe signal analysis. The analysis emphasizes real-time entry and exit signals, risk-reward ratios, and multi-timeframe updates for informed trading decisions.
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell 2500 Growth Benchmark
Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) has been removed from the Russell 2500 Growth Benchmark, according to an announcement on June 29, 2026. This change in index inclusion is significant for investors tracking growth-oriented small-cap pharmaceutical companies. Concurrently, the company was also dropped from the Russell Small Cap Comp Growth Benchmark and the Russell 2000 Growth Benchmark, but was added to the Russell Microcap Value Benchmark Index and Russell 2000 Value Benchmark.
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell Small Cap Comp Growth Benchmark
Rigel Pharmaceuticals, Inc. (RIGL) has been removed from the Russell Small Cap Comp Growth Benchmark, as announced on June 29, 2026. This news follows a series of rebalancing events for the company, including being added to the Russell Microcap Value and Russell 2000 Value benchmarks, while also being dropped from other growth-oriented indices. The article also provides a company profile outlining Rigel's focus on developing therapies for hematologic disorders and cancer, including its key products TAVALISSE, REZLIDHIA, and GAVRETO.
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) added to Russell Microcap Value Benchmark Index
Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) has been added to the Russell Microcap Value Benchmark Index. This inclusion highlights the company's position within the microcap market segment. The article also provides recent news regarding Rigel's licensing deals and earnings reports.
Rigel Pharmaceuticals, Inc.(NasdaqGS: RIGL) added to Russell 2000 Value Benchmark
Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) has been added to the Russell 2000 Value Benchmark. This news follows several other announcements for the company, including its addition to the Russell Microcap Value Benchmark Index and its removal from the Russell 2000 Growth and Russell 3000E Growth Benchmarks. The biotechnology company focuses on developing therapies for hematologic disorders and cancer, with products like TAVALISSE, REZLIDHIA, and GAVRETO.
Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL
This article focuses on the enterprise value to EBIT forward for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL). It appears to be a financial data point presented within a TradingView context, indicating a specific financial metric for the company. The rest of the content consists of navigation, copyright, and promotional information from the TradingView platform.
Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – BX:RIGL
The article "Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – BX:RIGL" presents a financial metric for Rigel Pharmaceuticals, Inc. (RIGL) on the BX Swiss exchange. It shows the enterprise value to EBIT forward for the company, indicating the period, value, change, and percentage change of this metric. The article is sourced from TradingView and includes standard disclaimers regarding market and reference data providers.
Price to earnings forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL
This article provides the forward Price to Earnings (P/E) ratio for Rigel Pharmaceuticals, Inc. (RIGL). It lists the current period value and any changes in value and percentage. The data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL
This article provides financial information for Rigel Pharmaceuticals, Inc. (RIGL) as presented on TradingView. It displays the company's enterprise value to EBIT forward, though specific data values are not present in this excerpt. The page structure indicates sections for overview, financials, news, and additional analysis.
Price to sales forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL
This article provides financial information for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), specifically detailing its forward price-to-sales ratio. It indicates that the market was closed at the time of publication, with no trades observed. The data is presented within the context of a TradingView platform page, emphasizing financial metrics for this pharmaceutical major.
Enterprise value to revenue forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL
This article provides the enterprise value to revenue forward for Rigel Pharmaceuticals, Inc. (RIGL). It lists the company's financial overview and is presented on the TradingView platform. The content primarily focuses on this specific financial metric for RIGL.
A40EFY Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rigel Pharmaceuticals, Inc. (A40EFY) stock, including analyst price targets and predictions for 2027. It details the current stock price, recent performance, and key financial metrics like earnings, revenue, and market capitalization. The article also addresses frequently asked questions about the company's stock and provides information on its upcoming earnings report.
Enterprise value to EBITDA forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL
This article displays financial data for Rigel Pharmaceuticals, Inc. (RIGL) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its Enterprise Value to EBITDA (forward). The page indicates the market was closed at the time of viewing, with no trades reported.
Rigel Pharmaceuticals, Inc. Actuals & Estimates (DUS:RI2)
This article provides an overview of Rigel Pharmaceuticals, Inc. (DUS:RI2) financials, including actuals and estimates for income, balance sheet, and cash flow. It also details analysts' price targets, historical stock performance, upcoming earnings dates, and current financial metrics such as revenue, net income, EBITDA, and employee count. The stock does not currently pay dividends.
RIGL Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rigel Pharmaceuticals, Inc. (RIGL) stock, including analyst price targets, historical stock performance, and financial data. Analysts have a maximum price estimate of 64.77 CHF and a minimum of 31.99 CHF for RIGL. The article also details recent stock movements, volatility, market capitalization, and upcoming earnings reports for the company.
Rigel (RIGL) director sells 2,500 shares under 10b5-1 plan for tax withholding
Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share, totaling $87,500, under a Rule 10b5-1 trading plan. This sale was explicitly for covering tax withholding obligations arising from the vesting of restricted stock units, not for investment purposes. After this transaction, Ali-Jackson directly holds 10,125 shares.
RI2 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rigel Pharmaceuticals, Inc. (RI2) stock, including analyst price targets and ratings. It also offers key financial data such as past earnings, revenue, net income, EBITDA, and upcoming earnings dates for the company. Additionally, the article addresses frequently asked questions about RI2's stock performance and how to trade it.
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $87,500 in stock
Rigel Pharmaceuticals director Ali-Jackson Kamil sold $87,500 worth of common stock on June 22, 2026, to cover tax withholding obligations from vested restricted stock units. The company's shares are currently trading higher than the sale price, and InvestingPro analysis suggests they are undervalued despite a significant return over the past year. Rigel also reported strong Q1 2026 revenue growth and a new licensing agreement for a breast cancer drug, Veppanu.
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Form 144 RIGEL PHARMACEUTICALS INC For: 22 June By Investing.com
This article reports on a Form 144 filing for RIGEL PHARMACEUTICALS INC (RIGL) on June 22. Form 144 is a notice of the intent to sell restricted securities, signifying potential insider transactions. The article also provides a brief overview of current market data, including indices, commodities, and various stock performances, without offering specific details about the RIGL filing itself.
Rigel Pharmaceuticals (RIGL) CEO gets 31,700 performance-based options
Rigel Pharmaceuticals CEO Raul R. Rodriguez was granted 31,700 performance-based stock options, which fully vested on June 17, 2026, after a performance metric was met. The options have an exercise price of $22.49 per share, matching the closing price on the grant date of January 29, 2025, and expire on January 29, 2035. This transaction is considered a compensation-related acquisition rather than an open-market trade.
Form 144 RIGEL PHARMACEUTICALS INC For: 22 June By Investing.com
This article from Investing.com reports on a Form 144 filing for RIGEL PHARMACEUTICALS INC (RIGL) on June 22nd. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the filing date and company name, implying it's a routine financial disclosure update for investors.
Form 144 RIGEL PHARMACEUTICALS INC For: 22 June By Investing.com
This article provides details about a Form 144 filing for RIGEL PHARMACEUTICALS INC, dated June 22, and was published by Investing.com. It includes a disclaimer about the high risks involved in trading financial instruments and cryptocurrencies. The content primarily focuses on the notification itself rather than in-depth financial analysis.
[144] RIGEL PHARMACEUTICALS INC SEC Filing
This SEC Form 144 filing indicates that Kamil Ali-Jackson sold 2,500 shares of RIGEL PHARMACEUTICALS INC common stock on May 26, 2026, for proceeds of $72,925. The shares were restricted stock that vested on May 21, 2024. The filing provides details on the transaction and includes general information regarding Form 144 requirements.
Liquidity Mapping Around (RIGL) Price Events
This article from Stock Traders Daily analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to provide trading strategies and signals. It details key findings including sentiment analysis, risk-reward scenarios, and support/resistance levels across different time horizons. The report offers specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies.
Rigel Expands Oncology Portfolio with VEPPANU Global Rights
Rigel Pharmaceuticals has acquired exclusive global rights for VEPPANU (vepdegestrant) through an agreement with Arvinas, Inc. and Pfizer Inc. This $70 million upfront payment expands Rigel's oncology pipeline. While analysts rate RIGL stock a "Buy" with a $57.00 target, TipRanks' AI Analyst, Spark, rates it Neutral due to strong financial performance being offset by weak technical positioning and mixed corporate event impact.
Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Rigel Pharmaceuticals Inc (RIGL), noting its strong financial status and high operating efficiency. The company's current financial score is 7.99, placing it well within the pharmaceuticals industry. Rigel recently reported a 10.28% year-over-year revenue increase and a 24.39% year-over-year net profit increase, though specific details for several financial metrics were not yet disclosed.
Rigel Pharmaceuticals Inc (RIGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey reports on Rigel Pharmaceuticals Inc (RIGL), noting its current stock price, market capitalization, and P/E ratio. The primary focus of the article is the company's revenue breakdown; however, it states that relevant data for business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article provides a standard company overview lacking specific financial details in these areas.
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv
Arvinas Holding Company LLC, Pfizer, and Rigel Pharmaceuticals have received approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026. This approval removes regulatory hurdles for their previously announced licensing agreement, allowing them to advance their cooperation. The HSR antitrust review clearance is a critical step, indicating that the transaction is not expected to harm market competition, and is anticipated to accelerate the implementation of their licensing agreement terms.
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv
Arvinas Holding Company LLC, Pfizer, and Rigel Pharmaceuticals have received approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026. This approval removes regulatory obstacles, allowing them to proceed with a previously announced licensing agreement. The clearance is a critical step for strategic collaborations involving intellectual property and market access, indicating that the transaction is not expected to harm competition.
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel Pharmaceuticals, Inc. announced the closing of its licensing agreement for VEPPANU™ (vepdegestrant) with Arvinas, Inc. and Pfizer Inc. The agreement, effective as of June 11, 2026, followed the early termination of the Hart-Scott Rodino waiting period. Rigel made an upfront payment of $70.0 million and expects to make VEPPANU commercially available in August for the treatment of certain advanced or metastatic breast cancer.
Why (RIGL) Price Action Is Critical for Tactical Trading
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) stock, highlighting a neutral near and mid-term outlook but a strong long-term positive bias. It presents several AI-generated trading strategies, including long, momentum breakout, and short options, along with key support and resistance levels across different time horizons. The analysis emphasizes risk-reward ratios and multi-timeframe signal analysis for tactical trading.
Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals
Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals, exercised stock options worth $52,271 for 3,381 shares. The company shows positive revenue growth of 10.28% and a high gross margin of 92.17%, but struggles with a high debt-to-equity ratio of 0.11. The article also touches on valuation metrics, noting the company's strong market capitalization, above-average EPS, and its potential undervaluation based on P/E and EV/EBITDA ratios.
RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations
RIGEL PHARMACEUTICALS INC EVP Raymond J. Furey reported a tax-withholding disposition of 877 common shares on June 1, 2026, at $29.86 per share to cover tax obligations. This non-market transaction is classified as a routine tax-withholding disposition, not a discretionary sale. Following this transaction, Furey directly holds 50,936 common shares, indicating the disposition was minor relative to his overall holdings.
Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes
Rigel Pharmaceuticals' EVP & Chief Financial Officer, Dean L. Schorno, exercised stock options for 3,381 shares and withheld 928 shares to cover tax obligations. This transaction was a tax-withholding event, not an open-market sale, leaving him with 78,790 directly held shares. All share counts reflect a one-for-ten reverse stock split effective June 27, 2024.
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake
RIGEL PHARMACEUTICALS INC CEO Raul R. Rodriguez reported a Form 4 transaction where 2,424 shares of Common Stock were delivered on June 1, 2026, at $29.86 per share to cover tax obligations. This disposition is classified as routine tax withholding, not an open-market trade. Following the transaction, Rodriguez retains a significant direct holding of 279,593 shares of RIGEL Common Stock.
Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations
Rigel Pharmaceuticals EVP and Chief Commercial Officer, David A. Santos, reported a tax-related share disposition. He delivered 874 shares of common stock at $29.86 per share to cover tax obligations, which is a routine tax-withholding event, not an open-market sale. After this transaction, Santos still directly holds 61,996 shares, indicating his ownership position remains largely unchanged.
Rigel (RIGL) CMO uses 850 shares to cover stock tax liability
Rigel Pharmaceuticals Inc.'s EVP and Chief Medical Officer, Lisa Rojkjaer, disposed of 850 shares of common stock on June 1, 2026, to cover a tax liability. This transaction, valued at $29.86 per share, was a tax-withholding disposition, not an open-market sale or purchase. After this event, Ms. Rojkjaer directly owns 34,003 shares of Rigel common stock.
Rigel Pharmaceuticals (NasdaqGS:RIGL) Stock Forecast & Analyst Predictions
Rigel Pharmaceuticals (RIGL) is facing a forecast decline in earnings (33.2% per annum) and EPS (43.2% per annum) over the next three years, despite expected annual revenue growth of 6.9%. The company recently acquired global rights to the breast cancer therapy VEPPANU, which is expected to shape future upside, and analysts have updated price targets accordingly. Recent insider transactions show a mix of buying and selling activity, with several directors indicating intent to sell shares.
RIGL - Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks
Rigel Pharmaceuticals' future opportunities are driven by the expansion of its commercial portfolio and a diversified clinical pipeline, despite risks from product dependence and competition. Analysts have lifted their price target due to updated assumptions around long-term revenue growth, profit margins, and a higher future P/E multiple. The company recently provided 2026 guidance projecting total revenue between $275 million and $290 million and updated data from its Phase 1b study of R289 for myelodysplastic syndrome.
Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade
Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of common stock at an average price of $29.17 per share on May 26, 2026. This open-market transaction falls under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, the director directly holds 12,625 shares in the company.
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar
Kamil Ali-jackson, a Director at Rigel Pharmaceuticals Inc (RIGL), sold 2,500 shares of the company on May 26, 2026, reducing her holdings to 12,625 shares. This sale is part of a trend with no insider buys and two insider sells for RIGL over the last year. The stock is currently trading at $29.17 and is considered fairly valued based on its GuruFocus Value of $28.35.
